Global /Norway /Healthcare /Biotechnology /AZT
chevron_leftBack

ArcticZymes Technologies ASA

AZT
OSL: AZT Delayed
17.90NOK 1.7%
1.70 USD
As of 24 April 2025, ArcticZymes Technologies ASA has a market cap of $86.39M USD, ranking #21565 globally and #138 in Norway. It ranks #2150 in the Healthcare sector, and #661 in the Biotechnology industry.
Global Rank
21565
Country Rank
138
Sector Rank
2150
Industry Rank
661
Key Stats
Market Cap
$86.39MUSD
898.86M NOK
Enterprise Value
$62.95MUSD
663.02M NOK
Revenue (TTM)
$10.39MUSD
108.11M NOK
EBITDA (TTM)
$92.48KUSD
974.0K NOK
Net Income (TTM)
$727.74KUSD
7.57M NOK
EBITDA Margin
0.9%
Profit Margin
7%
PE Ratio
117.3
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Michael Akoh open_in_new
Employees
61
Founded
1990
Website
arcticzymes.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
1.7% 3.6% -2.8% 25% 3.4% -33%
Upcoming Earnings
Earnings Date
Thu, May 8

Markets

Exchange Ticker Price
Euronext Oslo Børs
MIC: XOSL
PRIMARY
AZT
ISIN: NO0010014632
Shares Out.:
51.071M1 Shares Float: 44.442M2
TV:
SA:
YF:
GF:
BA:
AZT
MS:
17.90 NOK
Nasdaq Stockholm
MIC: XSTO
BIOTECO (AZTO)
ArcticZymes Technologies ASA
ISIN: NO0010014632
TV:
SA:
YF:
GF:
BA:
MS:
17.75 NOK
London Stock Exchange
MIC: XLON
0DRV
ISIN: NO0010014632
TV:
SA:
YF:
GF:
BA:
MS:
14.50 GBP
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About ArcticZymes Technologies ASA

ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing in Norway, Germany, Lithuania, France, Italy, rest of Europe, the United States, and internationally. The company offers shrimp alkaline phosphatase for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays; salt active nuclease for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; double-strand specific DNases and derived kits for the removal of double stranded DNA; DNA/RNA polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining nucleic acids. It serves the molecular tools research and diagnostics, and biomanufacturing markets. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was founded in 1990 and is headquartered in Tromsø, Norway.

Similar Companies

Industry: Biotechnology (Norway)
Name
Market Cap diff.
Nykode Therapeutics AS
NYKD
$77.2M
803.3M NOK
-11%
Thor Medical ASA
TRMED
$76.9M
800.17M NOK
-11%
Hofseth BioCare ASA
HBC
$76.65M
797.5M NOK
-11%
Zelluna ASA
ZLNA
$33.05M
343.86M NOK
-62%
Lytix Biopharma AS
LYTIX
$32.8M
341.31M NOK
-62%
Industry: Biotechnology (Global)
Name
Market Cap diff.
Vertex Pharmaceuticals Inc.
VRTX
$126.59B
146K%
CSL Ltd.
CSL
$74.13B
116.09B AUD
86K%
Regeneron Pharmaceuticals, Inc.
REGN
$62.91B
73K%
Samsung Biologics Co.,Ltd.
207940
$52.85B
75.87T KRW
61K%
argenx SE
ARGX
$36.66B
32.22B EUR
42K%